CG
PRQR icon

Cutler Group’s ProQR Therapeutics PRQR Stock Holding History

Cutler Group’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,200
Closed -$16K – 5511
2022
Q1 		$16K Buy
+2,200
New +$7.37K ﹤0.01% 3246
2021
Q1 		– Sell
-1,800
Closed -$3K – 6140
2020
Q4 		$3K Buy
1,800
+1,200
+200% +$5.06K ﹤0.01% 3994
2020
Q3 		$2K Sell
600
-6,700
-92% -$35K ﹤0.01% 4099
2020
Q2 		$16K Buy
7,300
+3,000
+70% +$16.2K ﹤0.01% 2549
2020
Q1 		$11K Buy
+4,300
New +$33K ﹤0.01% 2667

Other funds holding PRQR

PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Cutler Group's PRQR Position: Q1 2024 in Review

Cutler Group reduced its ProQR Therapeutics (PRQR) stake by 8.7% in Q1 2024, selling an estimated $855 and leaving 4,200 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #1333.

Cutler Group first reported a position in PRQR in Q1 2020 and has held it in 17 quarters since. The position peaked at $107K in Q3 2021. 49 funds tracked by Wall St. Rank hold PRQR as of Q1 2024.

  • Cutler Group held 4,200 shares of ProQR Therapeutics worth $9K as of Q1 2024.
  • Cutler Group sold 400 ProQR Therapeutics shares in Q1 2024, an estimated $855.
  • ProQR Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1333 holding.
  • Cutler Group first reported a position in ProQR Therapeutics in Q1 2020 and has held it in 17 quarters since.
  • Cutler Group's ProQR Therapeutics position peaked at $107K in Q3 2021.
  • 49 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.